SNSofie Nyström

Sofie Nyström

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sofie Nyström has a total of 162 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spike protein and fibrin(ogen) interactions

    by Per Hammarstrom, Sofie Nystrom

  • Open Access

    Standardization of cross-site biophysical studies of bovine insulin amyloids is challenged by structural polymorphism

    by Sofie Nyström, Davide Odino, Annalisa Relini, Claudio Canale, Raffaella Parlato, Yari Knelissen, Alessia Lasorsa, Wouter H. Roos, Patrick C.A. van der Wel, Søren V. Hoffmann, et al.

    Protein structure can be analysed using a range of different techniques. Many of the available principal techniques for assessing protein structure are developed and optimized for natively folded proteins that are soluble. Amyloids are an alternative protein fold, often associated with protein malfunction and disease but are also found as the functional fold for some proteins. While functional amyloids, just like soluble globular proteins, commonly attain one specific and precise fold to exert its function, disease associated amyloids are often poorly soluble and structurally highly variable. This is known as structural polymorphism. To investigate to what extent molecular biophysics techniques can be standardized for studies of amyloid fibrils, five sites within the Horizon 2020 funded project MOlecular-Scale Biophysics Research Infrastructure (MOSBRI) addressed this issue via a joint research activity. For this study we selected bovine insulin as a convenient, accessible, and distributable amyloid model system. The benchmark comparable techniques for observing formed amyloid fibrils at the different sites were fluorescence spectroscopy of two amyloid ligands (ThT and pFTAA) and negative stain transmission electron microscopy. The outcome of this study yielded results with a large variability between different insulin amyloid fibril preparations, between sites, and within chemically identical preparations from one site. We mainly attribute these hard to control differences to the intrinsic polymorphic behaviour of insulin amyloid fibrils. We also present a range of experimental measurement techniques to highlight their potential use for studying amyloid structure and amyloid polymorphism.


  • Open Access

    Heat shock protein 10 as a chaperone modulating α‐synuclein amyloid fibril formation

    by Johan N. K. Larsson, Ranjeet Kumar, Fiamma Ayelen Buratti, Sofie Nyström, Pernilla Wittung‐Stafshede, Per Hammarström

    HSP10 is a well‐known human co‐chaperone that interacts with HSP60 to comprise the HSP60/10 chaperonin complex which upholds mitochondrial proteostasis. HSP10 also demonstrates independent roles in binding to misfolded proteins and interacts with several amyloidogenic client proteins. Using a variety of biophysical and biochemical methods, we studied the interactions of HSP10 with the amyloidogenic protein α‐synuclein (α‐syn) associated with Parkinson's disease. HSP10 efficiently inhibited fibril formation of wild type (WT) and disease‐mutant A30P α‐syn at sufficient concentrations of chaperone by both binding to α‐syn monomers and by blocking secondary nucleation on fibril surfaces. However, under sub‐stoichiometric conditions, below 1:5 (HSP10:α‐syn), the chaperone sequestered multiple A30P α‐syn monomers and thereby promoted nucleation of fibril formation with a magnitude comparable to the efficacy of seeding with preformed fibrils. The fibril formation acceleration effect of the HSP10 chaperone was client‐specific as it was observed for A30P but not WT α‐syn. Our results broaden the scope of HSP10 chaperone activity and can have implications for disease onset in synucleinopathies.


  • Open Access

    SARS-CoV-2 Spike Protein Amyloid Fibrils Impair Fibrin Formation and Fibrinolysis

    by Henrik Westman, Per Hammarström, Sofie Nyström

    Long COVID, or postacute sequelae of COVID-19 from SARS-CoV-2 infection, is a persistent debilitating disease affecting multiple systems and organs. Long COVID pathophysiology is a complex and not fully established process. One prevailing theory is that the formation of fibrin amyloid microclots (fibrinaloids), due to SARS-CoV-2 infection, can induce persistent inflammation and capillary blockage. An association between the amyloidogenic Spike protein of SARS-CoV-2 and impaired fibrinolysis was made when it was observed that fibrin clots formed in the presence of a mixture of amyloid fibrils from the spike protein mediated resistance to plasmin lysis. Here, we use purified components from the coagulation cascade to investigate the molecular processes of impaired fibrinolysis using seven amyloidogenic SARS-COV-2 Spike peptides. Five of seven Spike amyloid fibrils appeared not to substantially interfere with the fibrinogen-fibrin-fibrinolysis process in vitro, while two spike fibrils were active in different ways. Spike601 amyloid fibrils (sequence 601-620) impaired thrombin-mediated fibrin formation by binding and sequestering fibrinogen but did not affect fibrinolysis. On the contrary, fibrin clots formed in the presence of Spike685 amyloid fibrils (sequence 685-701) exhibited a marked resistance to plasmin-mediated fibrinolysis. We conclude that Spike685 amyloid fibrils can induce dense fibrin clot networks as well as incorporate fibrin into aggregated structures that resist fibrinolysis. Our study proposes a molecular mechanism for how the Spike protein of SARS-CoV-2 could contribute to the formation of fibrinolysis-resistant microclots observed in long COVID.


  • Open Access

    SARS-CoV-2 spike protein amyloid fibrils impair fibrin formation and fibrinolysis

    by Henrik Westman, Per Hammarström, Sofie Nyström

    Long COVID, also known as post-acute sequelae of COVID-19 (PASC) from SARS-CoV-2 infection, is a debilitating and persistent disease of multiple systems and organs. WHO reports a total of 778 million registered SARS-CoV-2 infections as of June 2025. Recent studies indicate that as many as 25% of COVID patients will experience at least one symptom of Long COVID. Long COVID pathophysiology is a complex and not fully established process. One prevailing theory is that the formation of fibrin amyloid microclots (fibrinaloids), due to SARS-CoV-2 infection, can induce persistent inflammation and capillary blockage. An association between the amyloidogenic Spike protein of SARS-CoV-2 and impaired fibrinolysis has previously been made when it was observed that fibrin clots formed in the presence of a mixture of amyloid fibrils from the spike protein displayed a resistance to plasmin-mediated lysis. Here we investigated the molecular processes of impaired fibrinolysis using seven amyloidogenic SARS-COV-2 Spike peptides. Five out of seven Spike amyloid fibrils appeared not to substantially interfere with the fibrinogen-fibrin-fibrinolysis process in vitro, while two spike fibrils were active in different ways. Spike601 amyloid fibrils (sequence 601-620) impaired thrombin mediated fibrin formation by binding and sequestering fibrinogen but did not affect fibrinolysis. On contrary fibrin clots formed in the presence of Spike685 amyloid fibrils (sequence 685-701) exhibited a marked resistance to plasmin mediated fibrinolysis. We conclude that Spike685 amyloid fibrils can induce dense fibrin clot networks, as well as incorporate fibrin into aggregated structures that resist fibrinolysis. These results demonstrate how the Spike protein of SARS-CoV-2 could contribute to the formation fibrinolysis-resistant microclots observed in long COVID.


  • Open Access

    Efficient Seeding of Cerebral Vascular Aβ-Amyloidosis by Recombinant AβM1-42 Amyloid Fibrils

    by Farjana Parvin, Johan N.K. Larsson, Walker S. Jackson, Sofie Nyström, Per Hammarström


  • Open Access

    Divergent Age-Dependent Conformational Rearrangement within Aβ Amyloid Deposits in APP23, APPPS1, and AppNL-F Mice

    by Farjana Parvin, Samuel Haglund, Bettina Wegenast-Braun, Mathias Jucker, Takashi Saito, Takaomi C. Saido, K. Peter R. Nilsson, Per Nilsson, Sofie Nyström, Per Hammarström

    Amyloid plaques composed of fibrils of misfolded Aβ peptides are pathological hallmarks of Alzheimer's disease (AD). Aβ fibrils are polymorphic in their tertiary and quaternary molecular structures. This structural polymorphism may carry different pathologic potencies and can putatively contribute to clinical phenotypes of AD. Therefore, mapping of structural polymorphism of Aβ fibrils and structural evolution over time is valuable to understanding disease mechanisms. Here, we investigated how Aβ fibril structures in situ differ in Aβ plaque of different mouse models expressing familial mutations in the AβPP gene. We imaged frozen brains with a combination of conformation-sensitive luminescent conjugated oligothiophene (LCO) ligands and Aβ-specific antibodies. LCO fluorescence mapping revealed that mouse models APP23, APPPS1, and AppNL-F have different fibril structures within Aβ-amyloid plaques depending on the AβPP-processing genotype. Co-staining with Aβ-specific antibodies showed that individual plaques from APP23 mice expressing AβPP Swedish mutation have two distinct fibril polymorph regions of core and corona. The plaque core is predominantly composed of compact Aβ40 fibrils, and the corona region is dominated by diffusely packed Aβ40 fibrils. Conversely, the AβPP knock-in mouse AppNL-F, expressing the AβPP Iberian mutation along with Swedish mutation has tiny, cored plaques consisting mainly of compact Aβ42 fibrils, vastly different from APP23 even at elevated age up to 21 months. Age-dependent polymorph rearrangement of plaque cores observed for APP23 and APPPS1 mice >12 months, appears strongly promoted by Aβ40 and was hence minuscule in AppNL-F. These structural studies of amyloid plaques in situ can map disease-relevant fibril polymorph distributions to guide the design of diagnostic and therapeutic molecules.


  • Open Access

    Divergent age-dependent conformational rearrangement within Aβ amyloid deposits in APP23, APPPS1, and App NL-F mice

    by Farjana Parvin, Samuel Haglund, Bettina Wegenast-Braun, Mathias Jucker, Takashi Saito, Takaomi C. Saido, K Peter R Nilsson, Per Nilsson, Sofie Nyström, Per Hammarström

    Amyloid plaques composed of fibrils of misfolded Aβ peptides are pathological hallmarks of Alzheimer’s disease (AD). Aβ fibrils are polymorphic in their tertiary and quaternary molecular structures. This structural polymorphism may carry different pathologic potency and can putatively contribute to clinical phenotypes of AD. Therefore, mapping of structural polymorphism of Aβ fibrils is valuable to understand disease mechanisms. Here, we investigated how Aβ fibril morphology in situ differs in Aβ plaque of different mouse models expressing familial mutations in the AβPP gene. We used a combination of conformation-sensitive luminescent conjugated oligothiophene (LCO) ligands, Aβ-specific antibodies, and different fluorescence microscopy techniques. LCO fluorescence mapping revealed that mouse models APP23, APPPS1, and App NL-F have different fibril structures depending on AβPP-processing genotype. Co-staining of Aβ-specific antibodies showed that individual plaques from APP23 mice, expressing Swedish mutations (NL) have two distinct fibril polymorph regions of core and corona. The plaque core is predominantly composed of compact Aβ40 fibrils and the corona region is dominated by diffusely packed Aβ40 fibrils. On the other hand, the APP knock-in mouse App NL-F , expressing Iberian mutation (F) along with Swedish mutation has tiny, cored plaques consisting mainly of compact Aβ42 fibrils, vastly different from APP23 even at elevated age up to 21 months. Age dependent polymorph maturation of plaque cores observed for APP23 and APPPS1 mice >12 months, was minuscule in App NL-F . These structural studies of amyloid plaques in situ can map disease-relevant fibril polymorph distributions to guide the design of diagnostic and therapeutic molecules. Significance: Alzheimer’s disease (AD) is associated with the formation of deposits in the brain known as Aβ-amyloid plaques. AD can emerge as a sporadic disease or due to familial mutations in genes encoding for Aβ precursor and processing proteins. The Aβ-amyloid found in plaques displays different structures in sporadic AD and in various types of familial AD. We hypothesize that understanding plaque morphology and development is crucial for understanding the initiation and progression of AD. We here compared amyloid structures in three of the most used mouse models of human Aβ-plaque formation. Our findings suggest significant differences in plaque morphologies and structural maturation processes during aging. Our results emphasize that strain-like differences of Aβ-amyloids develop as a function of Aβ precursor protein-processing genetics and age.

  • Open Access

    SARS-CoV-2 Spike amyloid fibrils specifically and selectively accelerates amyloid fibril formation of human prion protein and the amyloid β peptide

    by Johan Nk Larsson, Ebba Hellstrand, Per Hammarström, Sofie Nyström

    An increasing number of reports suggest an association between COVID-19 infection and initiation or acceleration of neurodegenerative diseases (NDs) including Alzheimer’s disease (AD) and Creutzfeldt-Jakob disease (CJD). Both these diseases and several other NDs are caused by conversion of human proteins into a misfolded, aggregated amyloid fibril state. The fibril formation process is self-perpetuating by seeded conversion from preformed fibril seeds. We recently described a plausible mechanism for amyloid fibril formation of SARS-CoV-2 spike protein. Spike-protein formed amyloid fibrils upon cleavage by neutrophil elastase, abundant in the inflammatory response to COVID-19 infection. We here provide evidence of significant Spike-amyloid fibril seeded acceleration of amyloid formation of CJD associated human prion protein (HuPrP) using an in vitro conversion assay. By seeding the HuPrP conversion assay with other in vitro generated disease associated amyloid fibrils we demonstrate that this is not a general effect but a specific feature of spike-amyloid fibrils. We also showed that the amyloid fibril formation of AD associated Aβ1-42 was accelerated by Spike-amyloid fibril seeds. Of seven different 20-amino acid long peptides, Spike532 ( 532 NLVKNKCVNFNFNGLTGTGV 551 ) was most efficient in seeding HuPrP and Spike601 ( 601 GTNTSNQVAVLYQDVNCTEV 620 ) was most effective in seeding Aβ1-42, suggesting substrate dependent selectivity of the cross-seeding activity. Albeit purely in vitro , our data suggest that cross-seeding by Spike-amyloid fibrils can be implicated in the increasing number of reports of CJD, AD, and possibly other NDs in the wake of COVID-19.


  • Open Access

    Viruses and amyloids - a vicious liaison

    by Per Hammarström, Sofie Nyström

    The crosstalk between viral infections, amyloid formation and neurodegeneration has been discussed with varying intensity since the last century. Several viral proteins are known to be amyloidogenic. Post-acute sequalae (PAS) of viral infections is known for several viruses. SARS-CoV-2 and COVID-19 implicate connections between amyloid formation and severe outcomes in the acute infection, PAS and neurodegenerative diseases. Is the amyloid connection causation or just correlation? In this review we highlight several aspects where amyloids and viruses meet. The evolutionary driving forces that dictate protein amyloid formation propensity are different for viruses compared to prokaryotes and eukaryotes, while posttranslational endoproteolysis appears to be a common mechanism leading up to amyloid formation for both viral and human proteins. Not only do human and viral proteins form amyloid irrespective of each other but there are also several examples of co-operativity between amyloids, viruses and the inter-, and intra-host spread of the respective entity. Abnormal blood clotting in severe and long COVID and as a side effect in some vaccine recipients has been connected to amyloid formation of both the human fibrin and the viral Spike-protein. We conclude that there are many intersects between viruses and amyloids and, consequently, amyloid and virus research need to join forces here. We emphasize the need to accelerate development and implementation in clinical practice of antiviral drugs to preclude PAS and downstream neurological damage. There is also an ample need for retake on suitable antigen targets for the further development of next generation of vaccines against the current and coming pandemics.